Instadose Pharma Corp.
Instadose Pharma Corp. (INSD) Revenue
Annual & quarterly revenue history · segment & region breakdown
INSD · revenue · updated Jun 9, 2026
Core revenue metrics
Trailing 12 monthsInstadose Pharma Corp. trailing twelve-month (TTM) revenue is $0.00B, an increase of 0.00% year-over-year from — in FY.
Revenue trend
– · AnnualRevenue history
| Fiscal year end | Revenue | Change | Growth |
|---|
About Revenue & Reporting
Revenue (also called sales, net sales, or turnover) is the total income Instadose Pharma Corp. receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.
Instadose Pharma Corp. reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in USD.
Data sourced from Instadose Pharma Corp.'s 10-K and 10-Q SEC filings via Financial Modeling Prep.
Frequently asked questions
INSD revenue · 4 questionsINSD's trailing twelve-month (TTM) revenue is $0.00B. That is an increase of 0.00% year-over-year from — in FY.
▸ Source: FMP · Instadose Pharma Corp. SEC filings · GAAP · Instadose Pharma Corp. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026